AstraZeneca (LON:AZN) Stock Rating Reaffirmed as Buy by Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by research analysts at Jefferies Financial Group in a note issued to investors on Friday, Digital Look reports. They presently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group‘s target price points to a potential upside of 25.94% from the company’s current price.

A number of other equities research analysts have also weighed in on AZN. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a £117 price objective on shares of AstraZeneca in a report on Tuesday, September 29th. Berenberg Bank reaffirmed a “buy” rating and set a £175 target price on shares of AstraZeneca in a report on Wednesday, October 7th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They issued an “outperform” rating and a £145 target price on the stock. Finally, Citigroup upped their price target on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of £153.57.

AstraZeneca Price Performance

LON:AZN traded up GBX 844 during mid-day trading on Friday, reaching £138.96. The stock had a trading volume of 39,680,727 shares, compared to its average volume of 29,690,658. The firm has a 50 day moving average price of £122.69 and a two-hundred day moving average price of £134.30. The stock has a market capitalization of £215.51 billion, a P/E ratio of 20.80, a P/E/G ratio of 0.86 and a beta of 0.21. AstraZeneca has a one year low of £114.04 and a one year high of £157.32. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89.

Insider Buying and Selling

In other news, insider Michel Demare purchased 2,500 shares of the company’s stock in a transaction on Monday, September 14th. The stock was acquired at an average price of £121.21 per share, with a total value of £303,025. 0.15% of the stock is owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.